<p>Peter Nara of Biological Mimetics, Inc. in the U.S. will use a new vaccine technology to produce non-infectious poliovirus-like particles that can be used in one highly effective, low-cost polio vaccine capable of inducing protective immunity against all circulating serotypes.</p>


Peter Nara of Biological Mimetics, Inc. in the U.S. will use a new vaccine technology to produce non-infectious poliovirus-like particles that can be used in one highly effective, low-cost polio vaccine capable of inducing protective immunity against all circulating serotypes.

Creating a Cross-Serotype Poliovirus VLP Vaccine

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

.css-1nxq281{overflow:hidden;display:inline-block;}.css-1nxq281 span{display:inline-block;}Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

Great ideas come from everywhere.